References

Ali, O. A., N. Huebsch, L. Cao, G. Dranoff, and D. J. Mooney. 2009. Infection-mimicking materials to program dendritic cells in situ. Nature Materials 8(2):151–158.

Badrinath, S., M. O. Dellacherie, A. Li, S. Zheng, X. Zhang, M. Sobral, J. W. Pyrdol, K. L. Smith, Y. Lu, S. Haag, H. Ijaz, F. Connor-Stroud, T. Kaisho, G. Dranoff, G.-C. Yuan, D. J. Mooney, and K. W. Wucherpfennig. 2022. A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature 606(7916):992–998.

Chervo, M. F., W. Qian, K. A. O. Martinez, J. Zhou, R. Shroff, C. Mancino, L. G. Rojas, F. Taraballi, J. P. Cooke, and J. D. Gollihar. 2024. 1034 development of HLA Class I expressing humanized patient-derived xenograft (Hu-Pdx) mouse models for the study of mRNA-based cancer vaccines in triple-negative breast cancer. BMJ Specialist Journals.

Chien, S., R. Bashir, R. M. Nerem, and R. Pettigrew. 2015. Engineering as a new frontier for translational medicine. Science Translational Medicine 7(281):281fs213.

Doudna, J. A., and E. Charpentier. 2014. The new frontier of genome engineering with CRISPR-Cas9. Science 346(6213):1258096.

Dronca, R. S., J. C. Jones, H. S. Murthy, P. P. Advani, R. D. Parrondo, S. Ailawadhi, G. L. Mazza, S. Confiado, A. Baskin, and G. S. Nowakowski. 2025. Cancer Care Beyond Walls (CCBW): A randomized pragmatic trial of home-based versus in-clinic cancer therapy administration. American Society of Clinical Oncology.

Engel, N. W., I. Steinfeld, D. Ryan, K. Anupindi, S. Kim, N. Wellhausen, L. Chen, K. Wilkins, D. J. Baker, P. C. Rommel, D. Jarocha, M. Gohil, Q. Zhang, M. C. Milone, J. A. Fraietta, M. Davis, R. M. Young, and C. H. June. 2025. Quadruple adenine base–edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease–engineered T cells. Proceedings of the National Academy of Sciences 122(20):e2427216122.

Flores, E. R., and W. G. Sawyer. 2024. Engineering cancer’s end: An interdisciplinary approach to confront the complexities of cancer. Cancer Cell 42(7):1133–1137.

Friedmann, T., and R. Roblin. 1972. Gene therapy for human genetic disease? Science 175(4025):949–955.

Haslam, A., and V. Prasad. 2019. Estimation of the percentage of U.S. patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Network Open 2(5):e192535.

Hodi, F. S., A. Giobbie-Hurder, K. Adu-Berchie, S. Ranasinghe, A. Lako, M. Severgnini, E. M. Thrash, J. L. Weirather, J. Baginska, M. P. Manos, E. J. Doherty, A. Stafford, H. Daley, J. Ritz, P. A. Ott, K. L. Pfaff, S. J. Rodig, C. H. Yoon, G. Dranoff, and D. J. Mooney. 2025. First-in-human clinical trial of vaccination with WDVAX, a dendritic cell–activating scaffold incorporating autologous tumor cell lysate, in patients with metastatic melanoma. Cancer Immunology Research 13(7):978–989.

Hofman, M. S., W. E. Lau, and R. J. Hicks. 2015. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: Clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 35(2):500–516.

Hong, M.-K., and D.-C. Ding. 2025. Early diagnosis of ovarian cancer: A comprehensive review of the advances, challenges, and future directions. Diagnostics 15(4):406.

Huynh, J., N. Nishimura, K. Rana, J. M. Peloquin, J. P. Califano, C. R. Montague, M. R. King, C. B. Schaffer, and C. A. Reinhart-King. 2011. Age-related intimal stiffening enhances endothelial permeability and leukocyte transmigration. Science Translational Medicine 3(112):112ra122.

Jadvar, H., J. Calais, S. Fanti, F. Feng, K. L. Greene, J. L. Gulley, M. Hofman, B. F. Koontz, D. W. Lin, M. J. Morris, S. P. Rowe, T. J. Royce, S. Salami, B. Savir-Baruch, S. Srinivas, and T. A. Hope. 2022. Appropriate use criteria for prostate-specific membrane antigen PET imaging. Journal of Nuclear Medicine 63(1):59–68.

Jin, L., Y. Tang, Y. Wu, J. B. Coole, M. T. Tan, X. Zhao, H. Badaoui, J. T. Robinson, M. D. Williams, and A. M. Gillenwater. 2020. Deep learning extended depth-of-field microscope for fast and slide-free histology. Proceedings of the National Academy of Sciences 117(52):33051–33060.

Jin, L., Y. Tang, J. B. Coole, M. T. Tan, X. Zhao, H. Badaoui, J. T. Robinson, M. D. Williams, N. Vigneswaran, A. M. Gillenwater, R. R. Richards-Kortum, and A. Veeraraghavan. 2024. DeepDOF-SE: Affordable deep-learning microscopy platform for slide-free histology. Nature Communications 15(1):2935.

Jørgensen, L. V., E. B. Christensen, M. B. Barnkob, and T. Barington. 2025. The clinical landscape of CAR NK cells. Experimental Hematology & Oncology 14(1):46.

Korfiatis, P., G. Suman, N. G. Patnam, K. H. Trivedi, A. Karbhari, S. Mukherjee, C. Cook, J. R. Klug, A. Patra, H. Khasawneh, N. Rajamohan, J. G. Fletcher, M. J. Truty, S. Majumder, C. W. Bolan, K. Sandrasegaran, S. T. Chari, and A. H. Goenka. 2023. Automated artificial intelligence model trained on a large data set can detect pancreas cancer on diagnostic computed tomography scans as well as visually occult preinvasive cancer on prediagnostic computed tomography scans. Gastroenterology 165(6):1533–1546.e1534.

Kundrod, K. A., M. Barra, A. Wilkinson, C. A. Smith, M. E. Natoli, M. M. Chang, J. B. Coole, A. Santhanaraj, C. Lorenzoni, and C. Mavume. 2023. An integrated isothermal nucleic acid amplification test to detect HPV16 and HPV18 DNA in resource-limited settings. Science Translational Medicine 15(701):eabn4768.

Kunz, P. L., D. Ferone, D. M. Halperin, S. Myrehaug, K. Herrmann, M. Pavel, B. Chasen, J. Capdevila, S. Tafuto, and D.-Y. Oh. 2024. Safety and time to response of [177luL Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study. American Society of Clinical Oncology.

Langer, R. 2025. My struggles and dreams as a chemical engineer. Annual Review of Chemical and Biomolecular Engineering 16(1):1–22.

Langer, R., and J. Folkman. 1976. Polymers for the sustained release of proteins and other macromolecules. Nature 263(5580):797–800.

Li, H., K. Bera, P. Toro, P. Fu, Z. Zhang, C. Lu, M. Feldman, S. Ganesan, L. J. Goldstein, N. E. Davidson, A. Glasgow, A. Harbhajanka, H. Gilmore, and A. Madabhushi. 2021. Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: Clinical trial validation. NPJ Breast Cancer 7(1):104.

Li, H., A. Aggarwal, P. Toro, P. Fu, S. S. Badve, J. Cuzick, A. Madabhushi, and M. A. Thorat. 2024. A prognostic and predictive computational pathology immune signature for ductal carcinoma in situ: Retrospective results from a cohort within the UK/ANZ DCIS trial. Lancet Digital Health 6(8):e562–e569.

Li, Y., X. Jing, Q. Liu, Y. Wang, Y. Zhang, X. Jia, X. Yang, and K. Chen. 2025. Theranostics targeting fibroblast activation protein in the pan‐cancer field. International Journal of Cancer.

Liu, E., D. Marin, P. Banerjee, H. A. Macapinlac, P. Thompson, R. Basar, L. Nassif Kerbauy, B. Overman, P. Thall, and M. Kaplan. 2020. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. New England Journal of Medicine 382(6):545–553.

Lundqvist, A., J. Philip McCoy, L. Samsel, and R. Childs. 2007. Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood 109(8):3603–3606.

Maes, J., S. Gesquiere, A. De Spiegeleer, A. Maes, and C. Van de Wiele. 2024. Prostate-specific membrane antigen biology and pathophysiology in prostate carcinoma, an update: Potential implications for targeted imaging and therapy. International Journal of Molecular Sciences 25(17):9755.

Mallak, N., S. R. O’Brien, D. A. Pryma, and E. Mittra. 2024. Theranostics in neuroendocrine tumors. The Cancer Journal 30(3):185–193.

Marin, D., Y. Li, R. Basar, H. Rafei, M. Daher, J. Dou, V. Mohanty, M. Dede, Y. Nieto, N. Uprety, S. Acharya, E. Liu, J. Wilson, P. Banerjee, H. A. Macapinlac, C. Ganesh, P. F. Thall, R. Bassett, M. Ammari, S. Rao, K. Cao, M. Shanley, M. Kaplan, C. Hosing, P. Kebriaei, L. J. Nastoupil, C. R. Flowers, S. M. Moseley, P. Lin, S. Ang, U. R. Popat, M. H. Qazilbash, R. E. Champlin, K. Chen, E. J. Shpall, and K. Rezvani. 2024. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: A Phase 1/2 trial. Nature Medicine 30(3):772–784.

Maude, S. L., T. W. Laetsch, J. Buechner, S. Rives, M. Boyer, H. Bittencourt, P. Bader, M. R. Verneris, H. E. Stefanski, and G. D. Myers. 2018. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine 378(5):439–448.

McHugh, K. J., T. D. Nguyen, A. R. Linehan, D. Yang, A. M. Behrens, S. Rose, Z. L. Tochka, S. Y. Tzeng, J. J. Norman, A. C. Anselmo, X. Xu, S. Tomasic, M. A. Taylor, J. Lu, R. Guarecuco, R. Langer, and A. Jaklenec. 2017. Fabrication of fillable microparticles and other complex 3D microstructures. Science 357(6356):1138–1142.

Mikhael, P. G., J. Wohlwend, A. Yala, L. Karstens, J. Xiang, A. K. Takigami, P. P. Bourgouin, P. Chan, S. Mrah, W. Amayri, Y. H. Juan, C. T. Yang, Y. L. Wan, G. Lin, L. V. Sequist, F. J. Fintelmann, and R. Barzilay. 2023. Sybil: A validated deep learning model to predict future lung cancer risk from a single low-dose chest computed tomography. Journal of Clinical Oncology 41(12):2191–2200.

Mishra, A., S. B. Huang, T. Dubash, R. Burr, J. F. Edd, B. S. Wittner, Q. E. Cunneely, V. R. Putaturo, A. Deshpande, E. Antmen, K. A. Gopinathan, K. Otani, Y. Miyazawa, J. E. Kwak, S. Y. Guay, J. Kelly, J. Walsh, L. T. Nieman, I. Galler, P. Chan, M. S. Lawrence, R. J. Sullivan, A. Bardia, D. S. Micalizzi, L. V. Sequist, R. J. Lee, J. W. Franses, D. T. Ting, P. A. R. Brunker, S. Maheswaran, D. T. Miyamoto, D. A. Haber, and M. Toner. 2025. Tumor cell–based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product. Nature Communications 16(1):32.

Mok, T., D. Camidge, S. Gadgeel, R. Rosell, R. Dziadziuszko, D.-W. Kim, M. Pérol, S.-H. Ou, J. Ahn, and A. Shaw. 2020. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Annals of Oncology 31(8):1056–1064.

Nagrath, S., L. V. Sequist, S. Maheswaran, D. W. Bell, D. Irimia, L. Ulkus, M. R. Smith, E. L. Kwak, S. Digumarthy, A. Muzikansky, P. Ryan, U. J. Balis, R. G. Tompkins, D. A. Haber, and M. Toner. 2007. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173):1235–1239.

NRC (National Research Council). 2009. A new biology for the 21st Century. Washington, DC: National Academies Press.

Olson, J. A., D. B. Leveson-Gower, S. Gill, J. Baker, A. Beilhack, and R. S. Negrin. 2010. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood, The Journal of the American Society of Hematology 115(21):4293–4301.

Peruzzi, P., C. Dominas, G. Fell, J. D. Bernstock, S. Blitz, D. Mazzetti, M. Zdioruk, H. Y. Dawood, D. V. Triggs, S. W. Ahn, S. K. Bhagavatula, S. M. Davidson, Z. Tatarova, M. Pannell, K. Truman, A. Ball, M. P. Gold, V. Pister, E. Fraenkel, E. A. Chiocca, K. L. Ligon, P. Y. Wen, and O. Jonas. 2023. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas. Science Translational Medicine 15(712):eadi0069.

Santini, J. T., Jr., M. J. Cima, and R. Langer. 1999. A controlled-release microchip. Nature 397(6717):335–338.

Sartor, O., J. De Bono, K. N. Chi, K. Fizazi, K. Herrmann, K. Rahbar, S. T. Tagawa, L. T. Nordquist, N. Vaishampayan, and G. El-Haddad. 2021. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. New England Journal of Medicine 385(12):1091–1103.

Sethna, Z., P. Guasp, C. Reiche, M. Milighetti, N. Ceglia, E. Patterson, J. Lihm, G. Payne, O. Lyudovyk, L. A. Rojas, N. Pang, A. Ohmoto, M. Amisaki, A. Zebboudj, Z. Odgerel, E. M. Bruno, S. L. Zhang, C. Cheng, Y. Elhanati, E. Derhovanessian, L. Manning, F. Müller, I. Rhee, M. Yadav, T. Merghoub, J. D. Wolchok, O. Basturk, M. Gönen, A. S. Epstein, P. Momtaz, W. Park, R. Sugarman, A. M. Varghese, E. Won, A. Desai, A. C. Wei, M. I. D’Angelica, T. P. Kingham, K. C. Soares, W. R. Jarnagin, J. Drebin, E. M. O’Reilly, I. Mellman, U. Sahin, Ö. Türeci, B. D. Greenbaum, and V. P. Balachandran. 2025. RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer. Nature 639(8056):1042–1051.

Sharp, P. A., C. L. Cooney, M. A. Kastner, J. Lees, R. Sasisekharan, M. B. Yaffe, S. N. Bhatia, T. E. Jacks, D. A. Lauffenburger, R. Langer, P. T. Hammond, and M. Sur M. 2011. The third revolution: Convergence of life sciences, physical sciences, and engineering. Washington: Massachusetts Institute of Technology.

Sharp, P., and S. Hockfield. 2017. Convergence: The future of health. Science 355(6325):589.

Shen, D., B. Xu, K. Liang, R. Tang, G. P. Sudlow, C. Egbulefu, K. Guo, A. Som, R. Gilson, D. Maji, S. Mondal, L. Habimana-Griffin, W. J. Akers, S. Li, Y. Liu, S. Bloch, S. Kurkure, Z. Nussinov, A. Seidel, S. D. Tsen, and S. Achilefu. 2020. Selective imaging of solid tumours via the calcium-dependent high-affinity binding of a cyclic octapeptide to phosphorylated annexin A2. Nature Biomedical Engineering 4(3):298–313.

Shmuylovich, L., C. M. O’Brien, K. Nwosu, and S. Achilefu. 2024. Frugal engineering-inspired wearable augmented reality goggle system enables fluorescence-guided cancer surgery. Scientific Reports 14(1):24402.

Siegel, R. L., T. B. Kratzer, A. N. Giaquinto, H. Sung, and A. Jemal. 2025. Cancer statistics, 2025. CA 75(1):10–45.

Silberstein, E. B. 2012. Radioiodine: The classic theranostic agent. Seminars in Nuclear Medicine 42(3):164–170.

Skerrett, E., Z. Miao, M. N. Asiedu, M. Richards, B. Crouch, G. Sapiro, Q. Qiu, and N. Ramanujam. 2022. Multicontrast pocket colposcopy cervical cancer diagnostic algorithm for referral populations. BME Frontiers 2022:9823184.

Spaulding, M. B., S. G. Fischer, and G. T. Wolf. 1994. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. Journal of Clinical Oncology 12(8):1592–1599.

Steuer, C. E., M. Behera, S. Kim, Z. Chen, N. F. Saba, R. N. Pillai, T. K. Owonikoko, F. R. Khuri, and S. S. Ramalingam. 2015. Atypical carcinoid tumor of the lung: A surveillance, epidemiology, and end results database analysis. Journal of Thoracic Oncology 10(3):479–485.

Tsai, L. L., W. W. Phillips, Y. P. Hung, C. Dominas, K. Deans, S. Ahn, B. Ferland, K. Weiss, M. Lanuti, H. Auchincloss, L. Schumacher, O. Jonas, and Y. L. Colson. 2023. First-in-human intrathoracic implantation of multidrug-eluting microdevices for in situ chemotherapeutic sensitivity testing as proof of concept in nonsmall cell lung cancer. Annals of Surgery 277(5):e1143–e1149.

Wang, W., E. M. Lollis, F. Bordeleau, and C. A. Reinhart-King. 2019. Matrix stiffness regulates vascular integrity through focal adhesion kinase activity. FASEB Journal 33(1):1199–1208.

Weber, J. S., M. S. Carlino, A. Khattak, T. Meniawy, G. Ansstas, M. H. Taylor, K. B. Kim, M. McKean, G. V. Long, R. J. Sullivan, M. Faries, T. T. Tran, C. L. Cowey, A. Pecora, M. Shaheen, J. Segar, T. Medina, V. Atkinson, G. T. Gibney, J. J. Luke, S. Thomas, E. I. Buchbinder, J. A. Healy, M. Huang, M. Morrissey, I. Feldman, V. Sehgal, C. Robert-Tissot, P. Hou, L. Zhu, M. Brown, P. Aanur, R. S. Meehan, and T. Zaks. 2024. Individualised neoantigen therapy MRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, Phase 2b study. Lancet 403(10427):632–644.

Wolchok, J. D., V. Chiarion-Sileni, P. Rutkowski, C. L. Cowey, D. Schadendorf, J. Wagstaff, P. Queirolo, R. Dummer, M. O. Butler, and A. G. Hill. 2024. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. New England Journal of Medicine 392(1):11.

Yala, A., C. Lehman, T. Schuster, T. Portnoi, and R. Barzilay. 2019. A deep learning mammography-based model for improved breast cancer risk prediction. Radiology 292(1):60–66.

Zhang, D. K., J. M. Brockman, K. Adu-Berchie, Y. Liu, Y. Binenbaum, I. de Lázaro, M. C. Sobral, R. Tresa, and D. J. Mooney. 2025. Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells. Nature Biomedical Engineering 9(2):268–278.